Novavax (NVAX) said Tuesday that preliminary results from a real-world study showed that its COVID-19 vaccine targeting the JN.1 strain led to fewer and less severe reactogenicity symptoms compared with Pfizer-BioNTech's mRNA 2024-2025 vaccine.
The biotech company said the study, conducted in partnership with the University of Utah Health, showed that the impact of symptoms on daily activities, such as work and family responsibilities, was lower in patients receiving Novavax's vaccine.
Novovax said that, on average, recipients of its vaccine experienced 1.7 symptoms compared with 2.8 systemic symptoms in Pfizer-BioNTech recipients.
Additionally, the company said 43.8% of Pfizer-BioNTech recipients experienced at least one symptom of grade 2 or higher compared with 24.2% of Novavax recipients.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。